

Ada W Y Leung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6232451/publications.pdf>

Version: 2024-02-01

9
papers

289
citations

1306789

7
h-index

1473754

9
g-index

9
all docs

9
docs citations

9
times ranked

652
citing authors

#	ARTICLE	IF	CITATIONS
1	DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation. <i>Journal of Controlled Release</i> , 2022, 345, 75-90.	4.8	4
2	What Drives Innovation: The Canadian Touch on Liposomal Therapeutics. <i>Pharmaceutics</i> , 2019, 11, 124.	2.0	19
3	Transition Metal Ions Promote the Bioavailability of Hydrophobic Therapeutics: Cu and Zn Interactions with RNA Polymerase II Inhibitor CX5461. <i>Chemistry - A European Journal</i> , 2018, 24, 6334-6338.	1.7	6
4	Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor. <i>Journal of Controlled Release</i> , 2018, 286, 1-9.	4.8	11
5	A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer. <i>Journal of Controlled Release</i> , 2017, 252, 50-61.	4.8	33
6	Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status. <i>Investigational New Drugs</i> , 2017, 35, 682-690.	1.2	27
7	A Perspective “can copper complexes be developed as a novel class of therapeutics?”. <i>Dalton Transactions</i> , 2017, 46, 10758-10773.	1.6	140
8	Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development. <i>PLoS ONE</i> , 2016, 11, e0153416.	1.1	40
9	Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments. <i>Nanomedicine</i> , 2014, 9, 501-522.	1.7	9